• InsuraGuest goes live with Guesty, the world’s leading end-to-end short-term rental property management software
• Property managers who use Guesty to manage their short-term rentals: rentals which are listed on multiple platforms such as Airbnb, HomeAway, Vrbo, TripAdvisor, Agoda, and Booking.com
• Company’s success has hinged not only the caliber of management but even more so on the power of its proprietary software platform.
• The InsuraGuest expanded platform integration now connects with 90% of all property management systems used by the biggest names in hospitality.

Technology has now become a key factor in the insurance industry, and it is generating significant changes. The combination of insurance and technology (insurtech) is disrupting the entire insurance industry by providing new cost saving solutions and better customer experiences. It is designed to deliver better processes and greater efficiencies utilizing advanced insurance technologies. A leader in the insurtech sector, InsuraGuest Technologies (TSX.V: ISGI) (OTCQB: ISGIF)  continues to expand an already impressive reach into multiple insurance markets. The company’s first target is the hospitality sector with intent to dominate what looks to be an incredibly lucrative sector. InsuraGuest Technologies’ latest landmark is the announcement that it has gone live on a vendor partnership with Guesty, the world’s leading end-to-end short-term rental property management software (https://ibn.fm/Fs82V). InsuraGuest will integrate with the Guesty property management software through its proprietary API, which will enable Guesty’s 60k US property managers to transfer certain liability exposures to the InsuraGuest carrier. By transferring certain liabilities to the InsuraGuest Hospitality Liability coverages, for a small fee of $11.95 per night (which is passed on to the guest), the covered short-term rental properties can lower their claim ratios and risk profiles, which may decrease their general liability and/or homeowners’ premiums. Alon Eitan, Guesty’s Director of Strategy & Business Development stated, “We are excited to launch our relationship with InsuraGuest. Providing our customers with access to vendors like InsuraGuest helps protect their properties while protecting their guests.” InsuraGuest Technologies is steamrolling the industry, signing agreements with property management systems and operators, continually expanding the reach of its network. The company’s success has hinged not only the caliber of management but even more so on the quality of its value proposition. With a solid foundation built on the power of its proprietary software platform, InsuraGuest Technologies intends to dominate multiple insuratech markets. Commenting on the latest partnership, Douglas Anderson, CEO and Chairman of InsuraGuest Technologies stated, “Being able to work with the world’s leading end-to-end short-term rental property management software company means InsuraGuest will have access to market its Hospitality Liability product to property managers who use Guesty to manage their short-term rentals; rentals which are listed on multiple platforms such as Airbnb, HomeAway, Vrbo, TripAdvisor, Agoda, and Booking.com.” The InsuraGuest expanded platform integration now connects with 90% of all property management systems used by the biggest names in hospitality. The appeal is obvious to operators. Liability usually has limitations and high deductibles. When these incidents are covered by a property’s general liability insurance it could cost a facility more than the actual event and drive-up premiums. InsuraGuest provides a layer of protection that responds to the property directly when guests experience mishaps. Using InsuraGuest may decrease a property’s general liability premiums, thus saving money, time and aggravation for hotel and vacation rental operators. InsuraGuest is transforming the way insurance is delivered – digital insurance reimagined, reinvented, and revolutionized. For more information, visit the company’s website at www.InsuraGuest.com. NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Mobile technology innovator Friendable is pioneering a new venue for marketing musicians and allowing fans more direct access to their favorite performers as part of an emerging trend in digital engagement
• Friendable’s Fan Pass app fills a void in the entertainment industry during the closure of in-person concert and convention venues during the COVID pandemic, providing an interactive stage for performers through a monthly app subscription
• Friendable has signed more than 700 artists since launching Fan Pass in July
• The company recently announced a growing list of “Pro Services” to help its entertainers build their brand online, ranging from logo design to set building
• The subscription includes an initial trial-basis offer, followed by a low monthly fee equating to a couple of song downloads

The year 2020 will undoubtedly be remembered in the annals of history for its social and political drama, an idea celebrated in social media memes that feature time travelers recoiling from the thought of visiting that particular point in time. One innovation to emerge from the year, however, was the advent of direct digital platform engagement between entertainers and their fans during a year when live, in-person performances were all but outlawed as a result of the COVID pandemic. The trend initially manifested as artists started posting brief performances on their social media channels to provide a bit of upbeat distraction during “coronavirus isolation,” ranging from Italian tenor Maurizio Marchini singing opera from his balcony and comedian Steve Martin playing banjo music from a glade of trees (https://ibn.fm/P26HI) to old-school rockers Blue Oyster Cult presenting a lockdown rendition of “Godzilla” with five band members streaming together from separate locations (https://ibn.fm/B2Qs0). The enthusiasm for such impromptu digital engagement led to its evolution as a way for fans missing out on music concerts and star-studded science fiction conventions to find live, real-time performances from their favorite artists online and even chat one-on-one with them for a modest price. Mobile technology and marketing innovators at Friendable (OTC: FDBL) are establishing themselves as pioneers in delivering this type of fan experience through a proprietary app available on Google Play and the Apple Store. Since launching in July, Friendable’s Fan Pass platform has added more than 500 artists to its roster. The company recently announced that it is enhancing its ability to provide musicians a customized stage by establishing its “Pro Services” offering for existing artists with plans to soon roll out the service to all new artists during their onboarding and sign-up process (https://ibn.fm/ArJCM). The Pro Services include logo design, website creation, social media communications, merchandising, set building and lighting, with plans to expand what is offered to artists as the platform grows. “Our vision for Fan Pass has always been one of supporting both the artists and their fans, and now that we have a variety of artists, live channels, performances and content it’s a natural fit to begin offering additional services that can only enhance each artist brand, as well as boost revenue opportunities on Fan Pass,” Friendable CEO Robert A. Rositano Jr. stated in making the announcement. “In many ways, we are similar to a venture capital firm that nurtures each of its startups with the tools for success; but, in our case, we don’t discriminate based on talent, ideas or stage of career.” Fan Pass offers initial access to subscribers for free on a trial basis, offering social media access to exclusive VIP experiences, interviews and behind-the-scenes content featuring favored artists, with monthly rates thereafter priced equal to a couple of song downloads. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers for free on a trial basis. Thereafter, subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, providing VIP access at a fraction of the cost of traditional face-to-face meetups. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Torrey Hills Capital is a leading investor and financial public relations firm that offers extensive expertise in investor relations, corporate communications and other market support operations
• The services provided to Imagin Medical will be overseen by Torrey Hills Founder and Principal Cliff Mastricola
• Imagin believes its proprietary imaging technology, the i/Blue Imaging System(TM), will establish a new standard of care in visualizing cancer during minimally invasive procedures
• Company’s current focus is bladder cancer, the 6^th most prevalent form of cancer and most expensive to treat

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has engaged the services of San Diego-based investor relations firm Torrey Hills Capital, Inc. to increase awareness of its products with an informed investor audience in both the U.S. and Canadian marketplaces.

Torrey Hills Capital is a leading investor and financial PR firm that specializes in small and microcap companies. Formed in 1998, the firm offers considerable expertise and experience in corporate communications, investor relations, non-deal roadshows, as well as other market support activities (https://ibn.fm/8cnR8).

Torrey Hills Capital will provide Imagin Medical with dedicated market awareness and investor relations services that will be overseen by Cliff Mastricola, founder and principal of the firm. Mastricola has extensive experience in advising and developing corporate finance strategies, especially debt and equity capital-related issues, as well as mergers and acquisitions, recapitalizations, valuations and helping private companies go public.

The agreement between Imagin and Torey Hills is subject to regulatory acceptance of applicable filings with the CSE. Signed for an initial period of three months at a monthly rate of $7,000, the agreement can be automatically extended if both parties are satisfied with the terms and achieved progress. Imagin also agreed to a one-time grant of 100,000 incentive stock options at a price of $0.49 (C$0.62) per share for a three-year period.

By contracting Torrey Hills Capital, Imagin Medical plans to increase public and investor awareness of its innovative imaging technology, the i/Blue Imaging System), that the company expects will establish a new standard of care in visualizing cancer during minimally invasive procedures. The company’s initial focus is bladder cancer, the sixth most prevalent forms of cancer in the United States and the most expensive one to treat, while also having one of the highest recurrence rates (https://ibn.fm/KdZpt).

The current standard of visualizing bladder cancer during surgery uses white light illumination, which is especially effective when it comes to visualizing cancerous tumors protruding above the bladder wall. However, with this method flat tumors look the same as normal tissue. This issue is successfully overcome with the use of blue light. The problem, however, is that blue light cannot be used in real-time during surgery, and requires surgeons to constantly switch back and forth between white and blue light images to get perspective.

The proprietary i/Blue Imaging System(TM) addresses the limitations surgeons face in this regard by simultaneously displaying both white-light and blue-light images side by side, in real time. Additionally, the technology is highly versatile and can be attached to most endoscopes on the market, which means hospitals would be able to adopt the innovative visualization system without having to replace their current instruments, resulting in significant cost savings.

According to Imagin Medical, this technology has the potential to revolutionize the current standard of care for bladder cancer patients and help position the company as a leading provider of effective solutions in the global bladder cancer market, which is expected to reach $4.71 billion by 2026 (https://ibn.fm/tTWOf). Imagin Medical also intends to expand its technology for multiple endoscopic procedures in the future, including laparoscopic, colorectal and thoracic procedures that use a variety of contrast agents and illumination sources.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• San Francisco-based MAZAKALI is leveraging its extensive cannabis investment and fundraising advisory experience on the ongoing boom in the industry
• The company foresees the Cannabis complex becoming a trillion-dollar market as society continues to adopt the plant’s use for a large range of medical and industrial purposes
• The inauguration of President Joe Biden is ushering in an era of federal government in which cannabis-friendly officials are being named to key advisory positions in his cabinet and the Democratic Party
• Cannabis is currently legal for medical use in 35 U.S. states and permitted for adult-use in 15 states and the District of Columbia

Market watchers appear to consider liberalization of federal laws regarding cannabis to be a foregone conclusion now that the inauguration of President Joe Biden has taken place. That, in turn, is leading to rosy expectations for cannabis consumption — especially in light of the ongoing march of state-by-state legalization amid a growing acceptance of cannabis for adult-use as well as medicinal purposes. Cannabis marketplace facilitator MAZAKALI is helping investors seize opportunities to build profitable portfolios in this high growth industry while also assisting companies that are looking to raise capital to fuel their growth. The San Francisco-based capital adviser oversees an online investment marketplace that handles direct investments in a diverse field of vetted opportunities while also serving highly funded clients with personalized portfolio management and an Outsourced Cannabis Investment Officer (“OCIO”) service for asset managers. Cannabis plays a key role in MAZAKALI’s mission — in 2016 the company began working specifically to help investors place capital and to help companies raise capital. MAZAKALI’s GreenPapers(R) inform investors and operators through insights into deep trends in the cannabis complex, predicting in 2017 that significant federal reform would take place this year with a Democratic victory in the White House. “We had been following public opinion polls on (cannabis) legalization and noticed a fairly precipitous decline in the opposition to legalization. As an example, from 2007 through (20)17 we saw opposition decline from 60 to 40 percent and support increase even more, from 30 to nearly 60 percent,” MAZAKALI founder and CEO Sumit Mehta said during an interview with Jeremy Neilson, CEO of Assure (https://ibn.fm/ZVSkT). “We then looked at other states-led rights issues that eventually became legal at a federal level and we saw fairly similar trajectories,” Mehta added. “We saw a meaningful uptick in the states that were passing cannabis legalization measures between 2015 and 2017, and knew that the majority of Americans would soon have legal access to this plant with countless stories to share about its medical impact.  We expected that this would further bolster the public support that was building, fueled further as media was also becoming far less reticent to cover this increasingly destigmatized topic.” Cannabis is currently legal for medical use in 35 U.S. states and permitted for adult-use in 15 states (https://ibn.fm/W3Bw1). Its use has been adopted by a wide age range of consumers, particularly as older populations turn to cannabidiol (“CBD”) for over-the-counter pain relief and sleep aids (https://ibn.fm/9kTlt). In further support for investor confidence, observers have noted that President Biden appears to be stocking his cabinet with several key cannabis-friendly advisers. He has named a strong supporter of cannabis legalization as his nominee to lead the Democratic National Committee (“DNC”) (https://ibn.fm/Miclc). “It is likely that Cannabis will prove to be the best performing asset class over the next decade…Hemp will prove to be a major contribution to farmer livelihood as well as industrial and economic output, with the Cannabis complex likely a trillion-dollar market in the making,” MAZAKALI states as part of its advisory profile (https://ibn.fm/q2uwE). For more information, visit the company’s website at www.MAZAKALI.com. NOTE TO INVESTORS: The latest news and updates relating to MAZAKALI are available in the company’s newsroom at https://ibn.fm/MAZAKALI

The coronavirus pandemic that has been raging on for over a year now has impacted every industry in some form. For security companies, they have quietly stepped up to the front line, assisting local governments and communities to cope with the widespread outbreak. Whether it has meant helping with safe patient transfer, securing isolated areas, or protecting travel routes, those in the security industry have made the list of mostly overlooked heroes fighting the resilient virus. Many stores increased various security measures to ensure that customers and employees were safe at all times. Add it up and it speaks to the amount of exposure to COVID-19 that security personnel have had to endure. It also speaks to the value of employing robots to relieve stretches in capacity utilization and deployment into areas considered at risk for contagion. Furthermore, what about stores that have been ordered closed for months on end? These can’t be neglected. There are heightened economic tensions due to COVID-19. Autonomous robot sentries, like those of Knightscope, are doing their part, standing guard protecting, monitoring, and recording the empty facilities to detour and protect against potential criminal activity (https://ibn.fm/EwY0O). Going forward, some experts are convinced that a growing combination of technology and human response teams will be implemented to meet increased demand for guarding (https://ibn.fm/gK8li). Knightscope currently offers a diverse product lineup to meet various security requirements. The award-winning K1 is a stationary robot optimized for use at ingress and egress points, albeit indoors or outdoors. To the point of coronavirus, the K1 can be equipped with cutting-edge Elevated Body Temperature (“EBT”) detection technology, warning of visitors or staff with a fever, a common symptom of viral infection (https://ibn.fm/fDDzk). The K3 model is an indoor-roving patroller, ideal for malls, warehouses, hospital, airports, and anywhere that it is necessary to cover a lot of internal square footage. The K5 unit is designed for securing large outdoor areas. All the models have some common features, namely 24/7/365 work capabilities (sans a little downtime for the rovers to re-charge, which they perform automatically). Each is complete with state-of-the-art KSOC (Knightscope Security Operations Center) browser-based user interface, which provides that security team with “smart eyes and ears” and real-time data feeds. The KSOC system includes 360-degree eye-level HD video streaming, people detection, facial recognition, automatic license plate recognition, thermal anomaly detection, and automatic signal detection. Knightscope customers have repeatedly praised the effectiveness of deploying the autonomous security robots. Where in use, there are many examples of higher numbers of citations and arrests and a decrease in crime volume (https://ibn.fm/AJv8a). Packed with features and supported with empirical evidence of results, the autonomous robots are found across a wide array of applications, including police forces (municipal and campus), casinos, hospitals, banks and many more. 2021 has gotten off to a strong start, with Knightscope bringing on its fifth casino client, signing a contract with a prominent medical supply company in Texas, adding a national grocery store chain and a shopping center in Arizona, while a property developer beefed up his fleet of Knightscope robots to three. The company also reached another shareholder milestone, crossing 18,000 investors this month. Throughout the pandemic, only select companies have been recognized in what the next stage of life could look like. Autonomous security robots impervious to germs certainly fit that bill. For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Hollywall Entertainment Inc. is currently working on expanding the company through the acquisition of businesses within its targeted industries
• Hollywall subsidiaries are already working on multiple projects, most notably its HWDC subsidiary’s focus on the smart city concept leveraging 5G technology, internet of things and other innovative technologies
• The global 5G market is estimated to reach $414.5 billion by 2027, achieving a CAGR of 43.9%
• The company has acquired Omnipoint Technology and has launched HW Vision, a unique provider of state-of-the-art telecommunications services
• The music catalog licenses held by Hollywall Music and the Hollywall Network include rare recordings and unreleased tracks that are in high demand

Hollywall Entertainment (OTC: HWAL) is a telecommunication, media, technology, broadcasting and entertainment company. Through various subsidiaries, Hollywall maximizes rights to its music, film, television, software and game libraries. Hollywall owns exclusive and nonexclusive rights to market, manufacture and distribute music master recordings performed by multiple platinum-selling acts. Hollywall was founded in 2009. The company currently has two corporate offices – one in Washington D.C. and the other in New York City. Hollywall Entertainment Inc. (Hollywall) Subsidiaries Hollywall has a portfolio of operating subsidiaries spanning various industries, including infrastructure development, 5G and telecommunications, broadcasting, education, media and entertainment. Hollywall is a minority majority-controlled consortium enterprise company led by founder and President/CEO Darnell Sutton, a highly recognized visionary and award-winning business and social leader. HWAL continues to expand its business enterprise to numerous city and state municipalities and government agencies throughout the country, including: Washington DC, New York, Virginia, Massachusetts, Pennsylvania, Texas and California, as well as within the Blackbelt regions of Alabama, Louisiana, Mississippi, Georgia and North Carolina, leading the way in developing and implementing solutions to work toward closing the broadband digital divide that has been forced upon the most vulnerable in underserved urban and rural communities nationwide. Hollywall Development Company (“HWDC”) HWDC builds, restores and creates “smart” cities/communities and fiber networks throughout the U.S. HWDC services, initiatives and investments include broadband and 5G networks, IOT, smart city technologies, energy, tele-medicine, tele-education, transportation, clean water, waste management and the development of green environments. HWDC employment growth opportunities continue to attract the industry’s best, brightest and most seasoned corporate executives to join its staff, as well as its ongoing efforts to develop highly effective and profitable strategic partnerships with investment banks, global capital funds, public financial and wealth management firms, construction and engineering companies, telecommunications companies, federal agencies, state and local governments, nonprofits, faith-based organizations and housing authorities. HWDC’s Smart Cities division aims to provide various services and solutions, such as fiber-optic networking, data centers, smart kiosks, charging stations, security and camera systems, smart traffic monitoring, emergency alert systems, gunshot detection, backup power solutions, smart connected buildings, connected and autonomous vehicles, intelligent transportation systems, advertising and more. HW Vision and Omnipoint Technology Inc. Hollywall Entertainment advanced its technological footprint by acquiring top United States telecommunications firm Omnipoint Technology Inc. in 2020. Through the formation of a new wholly owned subsidiary, HW Vision, Hollywall intends to offer state-of-the-art services in the continuously growing digital marketplace, such as:

• 5G and Fiber Network installation services
• Affordable high-speed internet access
• Telehealth services
• Domain hosting
• Web conferencing
• Managed internet services
• Nationwide unlimited talk, text and data cellphone plans
• Video broadcasting

In conjunction with its Omnipoint Technology partner, HW Vision has created and developed unique branding for streaming media programming, live television and on-demand content. Offerings from the HW Vision brand are expected to be available for purchase early in 2021. Hollywall Entertainment Digital Music Network and Hollywall TV The Hollywall Entertainment Digital Music Network (“HW Network”) has been constructed to sell single song downloads, artist album downloads and ringtones, as well as licensing music for commercial use. Hollywall Music is an owner of legacy music and video collector sets that are distributed to retail, wholesale and download or streaming services. This music library has been protected for over 20 years, and it contains some of the rarest and most coveted unpublished records by legends in the music industry. Market Outlook Covering various industries that are continuously expanding, such as telecommunications, media, technology, construction, infrastructure, entertainment and broadcasting, Hollywall is uniquely positioned to secure a prominent role and leverage continued growth opportunities for its subsidiaries. The 5G sector alone could generate significant interest and market opportunities for Hollywall via HWDC and its community-focused initiatives, including the development of smart cities. The global 5G market was estimated at $41.48 billion for 2020 and is expected to reach an impressive $414.5 billion by 2027, expanding at a CAGR of 43.9% (https://ibn.fm/mgXIu). Management Team Darnell Sutton is the Founder, CEO and Chairman of Hollywall Entertainment Inc. Mr. Sutton has over 40 years’ experience with many talents and vast experience as a veteran in the music recording industry, publishing, distribution, live entertainment, television, broadcasting, film and sports athlete, TV/film celebrity and artist management. Darnell Sutton has represented and worked with some of the greatest athletes and entertainers of our time, including the “King of Pop” Michael Jackson, former heavyweight boxing champion Mike Tyson, current Welterweight Boxing Champion Floyd Mayweather, tennis superstar Serena Williams, Julius “Dr. J” Erving and incomparable multiple Grammy award-winning performers such as The Jacksons, Patti Labelle, Roberta Flack, MC Hammer, Dionne Warwick and Mariah Carey… just to name a few. “Darnell Sutton, is one of the most exciting master communicators, creative developers and innovators of our time”…says, Tom Stein, Success Magazine. “After many years of developing, producing and acquiring some of the world’s finest entertainment properties, we are honored to present Hollywall Entertainment companies to the marketplace. We are thrilled to join forces and work with some of the most brilliant and talented Hollywood and Wall Street executives, who have a combined shared experience of industry-recognized excellence,” Sutton said in a news release. Roxanna Green is the Chief of Staff for Hollywall Entertainment Inc. She has over 30 years of diverse background experience ranging from corporate management to finance. Her experience includes providing corporate legal and financial guidance to both public and private companies, as well as spearheading audits, merger and acquisition negotiations, branding, marketing and public relations initiatives. She has spent the majority of her 30 years in the entertainment and media industry. She has worked with diverse institutions such as banks and securities firms, among others. For more information, visit the company’s website at www.Hollywall.com. NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at https://ibn.fm/HWAL

• Flaws in the U.S. health-care system revealed during COVID-19 pandemic
• Lack of medication adherence can lead to serious issues, including worsening of disease, possible death and increased costs
• United Medical offers solutions for poor patient-physician communication and inadequate medication knowledge

The COVID-19 pandemic has revealed flaws in the U.S. health-care system, including flaws that require patients and caregivers to take a more active and educated role. United Medical Equipment Business Solutions Network (“UME”) provides reliable resources and solutions to help providers work more proficiently, health-care systems work smarter, and patients live healthier lives.

“This pandemic is a watershed moment in American history, one we must seize upon to fix the most glaring problems in our health system. We can’t ignore one health crisis for the sake of another,” wrote American Medical Association CEO and executive VP James L. Madara, MD, in a recent article (https://ibn.fm/ixqFL).

A few of the flaws that Madara points out are unequal treatment based on location, ethnicity, affordability and access to health insurance. He calls for collaboration to disrupt the status quo and create a new, affordable, efficient and accessible system for all. However, he notes, many obstacles interfere with patient care.

Communication and a lack of education around the medicines administered play a large part in failed care plans, dosage errors, no-adherence and readmittance to hospitals. Not every patient has easy access to needed education, which is something UME is working to change.

When patients and their doctors communicate clearly and openly with one another, the better the level and execution of a care plan occurs. When communication is clear, the patient or caregiver better understands the health condition and the treatment options. Proper education around all over-the-counter and prescribed doses is essential to avoid missed, skipped or willfully ignored care plans.

Medication management is an essential part of any treatment plan. When a patient or caregiver understands the purpose, dosage, side effects and other unique qualities of the medications being prescribed, they have a higher success rate of follow through. Aging individuals need caregivers who also have access to this education, whether those caregivers are able to attend doctor appointments or not.

Collaboration between a patient and physician is essential to improve the patient’s health. The physician needs to know all medications being taken, including over-the-counter, herbal and alternatives, because they may interact with what is prescribed. The patient needs to be informed about what they are taking, as well as why and how the medications work.

A lack of adherence can lead to serious problems that include a worsening of disease, possible death and increased costs to both the patient and the overall health-care system. Poor provider-patient communication and inadequate knowledge about a drug are two large barriers in medication adherence (https://ibn.fm/MVVWn). United Medical has developed a solution to address these barriers: a free medication management app available for download on the Apple App Store and Google Play.

The free seven-day trial version of the Medication Management app has a medication dictionary with up-to-date information on medications. The dictionary provides an image and description of the physical drug as well as an overview, side effects to look for, interactions with food and other drugs, and more. The app also comes with a pill identifier and converters for weight, temperature, volume, height and dosage. The company’s newest, highly asked for feature — Medication Log-Reminder — allows users to log all their medications in one convenient location and set reminders to take their medications. The app is protected by HIPAA compliance for PHI. Subscriptions are also available that allow the user to access telehealth and additional services for a small monthly fee.

For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• HYB Holding Corp.’s subsidiary, Mediscan Inc., offers technology that can turn 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views
• Mediscan’s technology has multiple applications in lung, cardiac and musculoskeletal imaging and related applications
• A portable ultrasound scanner equipped with the Mediscan application can help detect and diagnose lung and cardiac tissue damage in COVID-19 patients, who cannot undergo regular imaging procedures while contagious
• Mediscan recently filed a provisional patent application with the United States Patent and Trademark Office for a System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support
• Global demand for enhanced diagnostic imaging has increased due to the urgency of providing early diagnosis in patients
• Mediscan technology is available through a software-as-a-service model, helping health care providers reduce costs and increase patient satisfaction by providing speedier, effective imaging services
• The company’s management team come from legal, business and technology backgrounds, giving Mediscan access to a broad array of applicable knowledge

HYB Holding (OTC: HYBG), through its Mediscan Inc. subsidiary, created a cloud-based software for ultrasound technology that reconstructs the analog two-dimensional grayscale visual image into a digital three-dimensional, high-definition quantifiable format. The Mediscan software application dramatically increases the medical professional’s ability to use existing ultrasound devices at the point of care to derive meaningful data-driven clinical evaluations of a patient’s pathology or trauma, facilitate support for treatment options, monitor the patient’s ongoing progress or regress, and document compliance with required protocols and procedures. The Mediscan application also integrates with all popular EMR systems. HYB Holding Corp. acquired all of Mediscan’s capital stock in a reverse acquisition transaction on November 13, 2020. On November 23, 2020, the shareholders of HYB Holding Corp. consented to a resolution changing its name to Healthtech Solutions Inc. The company’s operational focus for the immediate future will be on Mediscan’s continuing research and development of imaging, development of other medical solutions, and making strategic investments. Mediscan Technology Mediscan software transforms an ultrasound analog 2D grayscale image into a digital 3D HD format. When paired with a portable ultrasound machine, the software application can enable these detailed and quantifiable scans by on-the-scene medical professionals, such primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (“EMS”) personnel, and technicians in isolation wards and emergency rooms. Once an image has been captured in 2D, it is converted using a cloud-based software application process – a process that takes approximately one minute. The completed 3D image is viewed on the medical professional’s computer monitor, pad or smartphone at the point of service. This technique can generate 3D medical images of different organs, such as the heart, lungs, tendons, skin and nerves. This cloud-based software application for ultrasound devices is easy to use anywhere there is an internet connection. The application provides the convenience of point of care ultrasound with the image quality of CT or X-ray and the safety of very expensive MRI technology. For patients, it provides a convenient and comfortable medical experience. Mediscan has filed two patent applications with the United States Patent and Trademark Office, both for a System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support (https://ibn.fm/lpImS). The technology will initially be available as medical software-as-a-service (“SaaS”), resulting in cost-efficiency. The SaaS model eliminates the customer’s need for external hardware and software solutions, as well as technical maintenance. The SaaS model is already widely used in the health care industry, most notably for clinical information systems and supply chain management, revenue cycle management and billing. Benefits include increased patient and physician satisfaction, lower operational costs, better workflows and more. Per company data, the Mediscan system is fast and efficient, which could generate a significant cost reduction. Health and Wellness Applications Mediscan’s technology has shown success in musculoskeletal (“MSK”), lung and cardiac imaging, enabling rapid pathology evaluation. Scanning the lung and or the MSK sub-system, the application directly images the target area, saves it as a reference, and then compares it to previous images, helping to determine if the patient is progressing or regressing. The cardiac application combines imaging with a therapy system that detects and classifies cardiac myopathy conditions via an “entrainment” process similar to that used in treating tachycardia. This application also features a comparison function where the latest imagery is interpreted against previous vetted cardiac images to detect progression or regression. Mediscan’s technology can also be utilized on the wellness market for diagnostics and support in a wide range of situations, such as sports injuries, physical therapy and dermatological indications. COVID-19 Applications COVID-19 causes complications with patients’ cardiovascular and pulmonary systems. Mediscan’s technology could help meet the growing need for advanced diagnostic and monitoring imaging at the point of care. Portable ultrasounds equipped with Mediscan’s application are a flexible and easy-to-use solution for health care providers to evaluate, triage and diagnose COVID-19 effects on contagious patients in isolation where MRI, CT or PET Scans are not accessible. With this technology, health care providers can easily detect lung lesions or heart muscle shredding, which often appear in patients with COVID-19. Diagnostic Imaging Market Outlook With the increasing demand for early diagnosis and a widening scope of clinical applications, any promising technological advancements in the field constitute a significant investment opportunity. The global market is also being driven by technological advances in the diagnostic imaging industry. As standard ultrasound 2D greyscale images are generally the norm, and 3D imaging typically requires the use of CT, PET, MRI or X-ray technology, Mediscan’s application could have a dramatic impact on the medical imaging industry, meeting the need for imaging equipment and devices that can generate human anatomy data in 3D. The global market for diagnostic imaging was estimated at approximately $100 billion in 2016 (https://ibn.fm/xtInK) and was expected to grow steadily, creating a promising opportunity for Mediscan to distribute its technology and achieve its mission as a developer and distributor of medical imaging solutions designed for both long-term care and acute and emergency medical services. Management Team David Rubin is the Chairman and CEO of HYB Holding Corp. Mr. Rubin has been in the financial services business for over 20 years. Concurrently, he is also the CEO of Capital Stack LLC and CEO of eProdigy Financial LLC. Rubin attended Kingsborough Community College from 1985 to 1988. Manuel Iglesias is the President and a Director of HYB Holding Corp. Mr. Iglesias has practiced law since 1980, specializing in business law, merger and acquisitions, securities and health care. Mr. Iglesias served as President, CEO and a board member of Hygea Holdings Corp., which provided primary care medical services throughout Florida and Georgia. He served as the National Chairman of the Republican National Lawyers Association in 2019 and 2020. Mr. Igleisias was awarded his MBA degree from the University of Chicago in 1981, a Juris Doctorate from the University of Chicago in 1979, and a BS in Foreign Service from Georgetown University in 1976. Denis Kleinfeld is a Director of HYB Holdings Corp. and General Counsel and a Director of Mediscan Inc. Mr. Kleinfeld has extensive experience in business planning and regulatory compliance. Mr. Kleinfeld is a renowned expert in international tax and estate planning law. Kleinfeld received his Juris Doctorate from the Loyola University of Chicago School of Law in 1970. Richard F. Parker is the Chief Research Officer of Mediscan Inc. He developed the technology that is the foundation of Mediscan’s business plan. Before he joined Mediscan, Mr. Parker was employed as an engineer and business executive for 37 years. Previously, he was President and Chief Technology Officer of CytoWave LLC. Mr. Parker was awarded a patent for technology that supported a Method and Apparatus for Generating a Therapeutic Magnetic Waveform. During the past 10 years, Mr. Parker has published 14 papers and made numerous presentations focused on magnetic imaging and treatment of sports and equine injuries. He obtained his MSEE degree from the Georgia Institute of Technology in 1971. For more information, visit the company’s website at www.MyMediScan.com. NOTE TO INVESTORS: The latest news and updates relating to HYBG are available in the company’s newsroom at https://ibn.fm/HYBG

• CBD products in oil-based form have compromised bioavailability, according to experts
• CNSC’s Xceptol CBD products created with proprietary CiBiDinol technology that addresses absorption issues for superior efficacy
• Third-party Xceptol testing shows 300% increased gut absorption, 400% increased skin penetration when compared to mainstream CBD oil products

Growing in popularity in a myriad of markets, cannabidiol (“CBD”) is a phytocannabinoid that can mimic natural endocannabinoids in the human body for various therapeutic effects. Growing awareness around the use of oil-based CBD has led to skyrocketing popularity among the mainstream public despite bioavailability concerns among healthcare professionals and doctors (https://ibn.fm/d0Kab). CannAssist International (OTCQB: CNSC), a biotechnological pharmaceutical company and owner of Xceptor Labs, has sought to address this issue through its CiBiDinol technology that increases absorbability, bioavailability and shelf life for all CBD products marketed under its Xceptol consumer brand. Bioavailability – the amount of a substance required to produce a response in the human body – is a growing concern among health professionals and consumers interested in the use of CBD oil for the treatment of various health conditions. Higher bioavailability typically translates to increased effectiveness, leading many CBD users and practitioners to believe that most CBD products’ oil-based nature may reduce absorption because oil and water do not mix. “Cannabinoids are fat-loving molecules and have to traverse a cellular environment that is aqueous or watery,” said Dr. Patricia Frye, a member of the Society of Cannabis Clinicians. According to Dr. Frye, the effects of oil-based cannabis can be delayed when bioavailability is limited. CNSC’s CiBiDinol technology directly addresses this issue through a proprietary process that combines CBD molecules with penetration-enhancing cyclodextrin, which covers the surface of the molecule rendering it water dispersible. Marketed under the Xceptol consumer brand, CBD products created using CiBiDinol technology promise increased efficacy, absorption and bioavailability for superior results per dose. Third-party testing confirmed a 300% increase in gut absorption rate and a 400% increase in skin penetration compared to regular oil-based CBD (https://ibn.fm/8Cqm0). CNSC is taking CiBiDinol technology further into mainstream medicine through several regulatory moves, including a submission to the FDA’s bulk drug substance program along with a submission for safety evaluation to the National Science Foundation for Global Recognition. Along with addressing these regulatory issues, the company actively engaged in developing commerce pathways that include state pharmaceutical distribution through State Boards of Pharmacy and offering licensing arrangements for brand-consumer companies. Established in May 2017, CannAssist, headquartered in San Diego, California, with a management team that includes expert scientists, healthcare professionals and product research specialists.  The company’s proprietary CiBiDinol Technology aims to create superior CBD products with higher absorbability, efficacy and longer shelf life. Marketed under the Xceptol brand, CannAssist’s CBD products are sold online through the RangeMe product marketplace and multiple international sales channels throughout Central America, South America, South Africa, the EU, the UK and the Philippines. For more information, visit the company’s website at www.CannAssistInternational.com. NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC

• Ovarian cancer is a leading cause of death, causes more death than any other female reproductive system cancer
• POAI’s Helomics dedicated to improving clinical decision making for ovarian cancer patients
• Helomics has pioneered testing of drugs on patients’ own tumors to help oncologists individualize treatment options

According to the American Cancer Society, an estimated 21,750 women received a new diagnosis of ovarian cancer this year, and almost 14,000 women will die from the disease (https://ibn.fm/4yfJn). Those numbers make ovarian cancer the fifth-leading cause of cancer deaths in women; ovarian cancer causes more deaths than any other cancer of the female reproductive system. These are the numbers that Predictive Oncology (NASDAQ: POAI) is working to change.

For more than a year, Helomics, a wholly owned subsidiary of POAI, has been working with the University of Pittsburgh School of Medicine (“UPMC”) to study the use of artificial intelligence (“AI”) to improve clinical decision making for ovarian cancer patients (https://ibn.fm/88drd). The project, a joint collaborative agreement with UPMC called CancerQuest2020, kicked off in summer 2019.

The collaboration entails using Helomics’ AI platform and proprietary data to analyze the genomic and drug response profiles of women with ovarian cancer to evaluate predictive value in terms of response and non-response to different treatments.

“Helomics has pioneered the testing of drugs on the patient’s own tumor to help oncologists individualize treatment options — what we call functional precision medicine,” said Helomics chief innovation officer, Dr. Mark Collins. “We believe that by linking both the drug response profile and the genomic profile of the patient’s tumor using a machine learning approach, we can provide ‘multi-omic’ predictive models that will have greater decision-making impact than just genomics alone, which in turn will positively benefit oncologists and their patients.”

According to POAI, the predictive models “embody the knowledge from these profiles to create a ‘computational expert’ or a ‘virtual patient’ that can be queried. Predictive models such as these are also of high value to pharmaceutical companies as they can be used to quickly select patients for clinical trials and assess potential new drugs or biomarkers computationally (‘in silico’) before initiating expensive laboratory experiments. In short, Helomics’ predictive models will save time and money in the search for new targeted therapies” (https://ibn.fm/pFLn0).

Helomics brings to the project data generated from more than 150,000 tumor cases obtained from over 15 years of clinical testing on living patient tumors. That date includes drug response, genomic (mutations), transcriptomic (gene expression) and tissue-omic (tumor pathology) profiles that help predict drug response and outcome.

According to the company, “We have developed a unique technology that combines our clinically validated primary tumor cell assay and drug response data . . . together with proven artificial intelligence (‘AI’) to allow us to test potential drugs against patient tumor cells, much earlier in the drug discovery process. We believe this patient-centric approach will significantly improve the success of translating compounds into the clinic, saving time, cost, and most importantly getting therapies to patients more quickly” (https://ibn.fm/iqjra).

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI